{"protocolSection": {"identificationModule": {"nctId": "NCT01606007", "orgStudyIdInfo": {"id": "CV181-169"}, "secondaryIdInfos": [{"id": "2012-000679-18", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes", "officialTitle": "A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone."}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-07"}, "primaryCompletionDateStruct": {"date": "2014-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-05-23", "studyFirstSubmitQcDate": "2012-05-24", "studyFirstPostDateStruct": {"date": "2012-05-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-12-19", "resultsFirstSubmitQcDate": "2015-09-22", "resultsFirstPostDateStruct": {"date": "2015-10-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-03-29", "lastUpdatePostDateStruct": {"date": "2017-05-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1282, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1: Saxagliptin+Metformin XR+Placebo", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Saxagliptin", "Drug: Metformin XR", "Drug: Placebo matching with Dapagliflozin"]}, {"label": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Metformin XR", "Drug: Dapagliflozin", "Drug: Placebo matching with Saxagliptin"]}, {"label": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Saxagliptin", "Drug: Metformin XR", "Drug: Dapagliflozin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "Tablets, Oral, 5mg , Once daily, 24 weeks", "armGroupLabels": ["Arm 1: Saxagliptin+Metformin XR+Placebo", "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks", "armGroupLabels": ["Arm 1: Saxagliptin+Metformin XR+Placebo", "Arm 2: Dapagliflozin+Metformin XR+Placebo", "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR"], "otherNames": ["Glucophage XR"]}, {"type": "DRUG", "name": "Dapagliflozin", "description": "Tablets, Oral, 10mg , Once daily, 24 weeks", "armGroupLabels": ["Arm 2: Dapagliflozin+Metformin XR+Placebo", "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR"], "otherNames": ["BMS-512148"]}, {"type": "DRUG", "name": "Placebo matching with Dapagliflozin", "description": "Tablets, Oral, 0mg, Once daily, 24 weeks", "armGroupLabels": ["Arm 1: Saxagliptin+Metformin XR+Placebo"]}, {"type": "DRUG", "name": "Placebo matching with Saxagliptin", "description": "Tablets, Oral, 0mg, Once daily, 24 weeks", "armGroupLabels": ["Arm 2: Dapagliflozin+Metformin XR+Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.", "timeFrame": "Baseline (Week 0) and at Week 24"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at week 24 in the doubleblind period, including observations prior to rescue.", "timeFrame": "Baseline (Week 0) and at Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.", "timeFrame": "Baseline (Week 0) and at Week 24"}, {"measure": "Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Therapeutic glycemic response is defined as HbA1c \\<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "timeFrame": "At Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Body Weight at Week 24", "description": "Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.", "timeFrame": "Baseline (Week 0) and at Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with Type 2 diabetes mellitus (T2DM) with HbA1c \u2265 8.0% and \u2264 12.0%\n* Stable metformin therapy dose of \u2265 1500mg for at least 8 weeks prior to screening\n* Body mass index (BMI) \u2264 45.0kg/m2\n\nExclusion Criteria:\n\n* Estimated glomerular filtration rate (eGFR) \\< 60mL/min/1,73m2 and Serum Creatinine (Scr) \u2265 1.5 mg/dL in males or \u2265 1.4 mg/dL in females\n* Uncontrolled hypertension Systolic Blood Pressure (SBP) \u2265 160mmHg and/or Diastolic Blood Pressure (DBP) \u2265 100mmHg\n* Hepatic disease\n* Cardiovascular disease within 3 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Central Alabama Research", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Central Alabama Research", "city": "Homewood", "state": "Alabama", "zip": "35244", "country": "United States", "geoPoint": {"lat": 33.47177, "lon": -86.80082}}, {"facility": "Terence T. Hart, Md", "city": "Muscle Shoals", "state": "Alabama", "zip": "35662", "country": "United States", "geoPoint": {"lat": 34.74481, "lon": -87.66753}}, {"facility": "International Institute Of Clinical Research", "city": "Ozark", "state": "Alabama", "zip": "36360", "country": "United States", "geoPoint": {"lat": 31.45906, "lon": -85.64049}}, {"facility": "Clinical Research Advantage", "city": "Mesa", "state": "Arizona", "zip": "85206", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"facility": "Elite Clinical Studies, Llc", "city": "Phoenix", "state": "Arizona", "zip": "85018", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Genova Clinical Research", "city": "Tucson", "state": "Arizona", "zip": "85704", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Medical Investigations, Inc.", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Aureus Research, Inc.", "city": "Little Rock", "state": "Arkansas", "zip": "72211", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Southland Clinical Research Center, Inc.", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Torrance Clinical Research", "city": "Lomita", "state": "California", "zip": "90717", "country": "United States", "geoPoint": {"lat": 33.79224, "lon": -118.31507}}, {"facility": "National Research Inst", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Providence Clinical Research", "city": "North Hollywood", "state": "California", "zip": "91606", "country": "United States", "geoPoint": {"lat": 34.17223, "lon": -118.37897}}, {"facility": "Diabetes Medical Center Of California", "city": "Northridge", "state": "California", "zip": "91325", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Mehrdad Kevin Ariani Md, Inc.", "city": "Northridge", "state": "California", "zip": "91325", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Lucita M. Cruz,Md.,Inc.", "city": "Norwalk", "state": "California", "zip": "90650", "country": "United States", "geoPoint": {"lat": 33.90224, "lon": -118.08173}}, {"facility": "Center For Clinical Trials, Llc.", "city": "Paramount", "state": "California", "zip": "90723", "country": "United States", "geoPoint": {"lat": 33.88946, "lon": -118.15979}}, {"facility": "Center For Clinical Trials Of Sacramento, Inc.", "city": "Sacramento", "state": "California", "zip": "95823", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Trinitas Research, Inc", "city": "San Jose", "state": "California", "zip": "95116", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Orange County Research Center", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Clinical Research Advantage", "city": "Colorado Springs", "state": "Colorado", "zip": "80906", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Infocus Clinical Research", "city": "Denver", "state": "Colorado", "zip": "80211", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Lynn Institute Of Denver", "city": "Denver", "state": "Colorado", "zip": "80246", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Southeast Clinical Research, Llc", "city": "Chiefland", "state": "Florida", "zip": "32626", "country": "United States", "geoPoint": {"lat": 29.47496, "lon": -82.85984}}, {"facility": "Clinical Therapeutics Corporation", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Southeast Clinical Research, Llc", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Fpa Clinical Research", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Newphase Clinical Trials, Inc.", "city": "Miami Beach", "state": "Florida", "zip": "33140", "country": "United States", "geoPoint": {"lat": 25.79065, "lon": -80.13005}}, {"facility": "Clinical Research Of Miami, Inc.", "city": "Miami", "state": "Florida", "zip": "33126", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Advanced Pharma Cr, Llc", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Omega Research Consultants, Llc", "city": "Orlando", "state": "Florida", "zip": "32804", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Palm Harbor Medical Associates", "city": "Palm Harbor", "state": "Florida", "zip": "34684", "country": "United States", "geoPoint": {"lat": 28.07807, "lon": -82.76371}}, {"facility": "Andres Patron, Do Pa", "city": "Pembroke Pines", "state": "Florida", "zip": "33026", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"facility": "Endocrine Research Solutions, Inc.", "city": "Roswell", "state": "Georgia", "zip": "30076", "country": "United States", "geoPoint": {"lat": 34.02316, "lon": -84.36159}}, {"facility": "Cedar Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607-4559", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Deerbrook Medical Associates", "city": "Vernon Hills", "state": "Illinois", "zip": "60061", "country": "United States", "geoPoint": {"lat": 42.21947, "lon": -87.97952}}, {"facility": "Clinical Research Advantage", "city": "Council Bluffs", "state": "Iowa", "zip": "51503", "country": "United States", "geoPoint": {"lat": 41.26194, "lon": -95.86083}}, {"facility": "Horizon Research Group Of Opelousas, Llc", "city": "Eunice", "state": "Louisiana", "zip": "70535", "country": "United States", "geoPoint": {"lat": 30.49437, "lon": -92.41763}}, {"facility": "Associated Internal Medicine Specialists", "city": "Battle Creek", "state": "Michigan", "zip": "49015", "country": "United States", "geoPoint": {"lat": 42.3173, "lon": -85.17816}}, {"facility": "Harris And Associates, P.C.", "city": "Detroit", "state": "Michigan", "zip": "48235", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Patterson Medical Clinic", "city": "Florissant", "state": "Missouri", "zip": "63031", "country": "United States", "geoPoint": {"lat": 38.78922, "lon": -90.32261}}, {"facility": "Bellevue Family Practice", "city": "Bellevue", "state": "Nebraska", "zip": "68005", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Clinical Research Advantage", "city": "Elkhorn", "state": "Nebraska", "zip": "68022", "country": "United States", "geoPoint": {"lat": 41.28639, "lon": -96.23447}}, {"facility": "Clinical Research Advantage", "city": "Fremont", "state": "Nebraska", "zip": "68025", "country": "United States", "geoPoint": {"lat": 41.43333, "lon": -96.49808}}, {"facility": "Clinical Research Advantage", "city": "Omaha", "state": "Nebraska", "zip": "68130", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "South Jersey Medical Associates, P.A.", "city": "Blackwood", "state": "New Jersey", "zip": "08012", "country": "United States", "geoPoint": {"lat": 39.80234, "lon": -75.06406}}, {"facility": "Central Jersey Health And Medical Research", "city": "Elizabeth", "state": "New Jersey", "zip": "07205", "country": "United States", "geoPoint": {"lat": 40.66399, "lon": -74.2107}}, {"facility": "Southgate Medical Group", "city": "West Seneca", "state": "New York", "zip": "14224", "country": "United States", "geoPoint": {"lat": 42.85006, "lon": -78.79975}}, {"facility": "Metrolina Internal Medicine", "city": "Charlotte", "state": "North Carolina", "zip": "28204", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Triad Clinical Trials, Llc", "city": "Greensboro", "state": "North Carolina", "zip": "27410", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Diabetes & Endocrinology Consultants", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "Pmg Research Of Winston-Salem, Llc", "city": "Winston-salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Daystar Clinical Resarch, Inc.", "city": "Akron", "state": "Ohio", "zip": "44313", "country": "United States", "geoPoint": {"lat": 41.08144, "lon": -81.51901}}, {"facility": "Sterling Research Grp, Ltd.", "city": "Cincinnati", "state": "Ohio", "zip": "45246", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Rapid Medical Research, Inc.", "city": "Cleveland", "state": "Ohio", "zip": "44122", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Primed Clinical Research", "city": "Dayton", "state": "Ohio", "zip": "45419", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Physicians Research, Inc.", "city": "Zanesville", "state": "Ohio", "zip": "43701", "country": "United States", "geoPoint": {"lat": 39.94035, "lon": -82.01319}}, {"facility": "Lynn Institute Of Norman", "city": "Norman", "state": "Oklahoma", "zip": "73069", "country": "United States", "geoPoint": {"lat": 35.22257, "lon": -97.43948}}, {"facility": "Willamette Valley Clinical Studies", "city": "Eugene", "state": "Oregon", "zip": "97404", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Oregon Clinical Research", "city": "Portland", "state": "Oregon", "zip": "97220", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Heritage Valley Medical Group", "city": "Beaver", "state": "Pennsylvania", "zip": "15009", "country": "United States", "geoPoint": {"lat": 40.69534, "lon": -80.30478}}, {"facility": "Wellmon Family Practice", "city": "Shippensburg", "state": "Pennsylvania", "zip": "17257", "country": "United States", "geoPoint": {"lat": 40.05065, "lon": -77.52026}}, {"facility": "Tlm Medical Services", "city": "Columbia", "state": "South Carolina", "zip": "29204", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "Palmetto Clinical Trial Services Llc", "city": "Fountain Inn", "state": "South Carolina", "zip": "29644", "country": "United States", "geoPoint": {"lat": 34.68901, "lon": -82.19567}}, {"facility": "Holston Medical Group", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "Holston Medical Group", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Pmg Research Of Knoxville", "city": "Knoxville", "state": "Tennessee", "zip": "37912", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "Arlington Family Research Center, Inc.", "city": "Arlington", "state": "Texas", "zip": "76012", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Padre Coast Clinical Research", "city": "Corpus Christi", "state": "Texas", "zip": "78404", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "Dallas Diabetes & Endocrine Center", "city": "Dallas", "state": "Texas", "zip": "75230-2548", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Excel Clinical Research, Llc", "city": "Houston", "state": "Texas", "zip": "77035", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "North Hills Medical Research, Inc.", "city": "North Richland Hills", "state": "Texas", "zip": "76180", "country": "United States", "geoPoint": {"lat": 32.8343, "lon": -97.2289}}, {"facility": "Med-Olam Clinical Research", "city": "Pasadena", "state": "Texas", "zip": "77504", "country": "United States", "geoPoint": {"lat": 29.69106, "lon": -95.2091}}, {"facility": "Sam Clinical Research Center", "city": "San Antoinio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Covenant Clinical Research, Pa", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Hillcrest Family Health Center", "city": "Waco", "state": "Texas", "zip": "76710", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Val R. Hansen, M.D.", "city": "Bountiful", "state": "Utah", "zip": "84010", "country": "United States", "geoPoint": {"lat": 40.88939, "lon": -111.88077}}, {"facility": "Highland Clinical Research", "city": "Salt Lake City", "state": "Utah", "zip": "84124", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Southwestern Vermont Med Cntr", "city": "Bennington", "state": "Vermont", "zip": "05201", "country": "United States", "geoPoint": {"lat": 42.87813, "lon": -73.19677}}, {"facility": "Hampton Roads Center For Clinical Research, Inc.", "city": "Suffolk", "state": "Virginia", "zip": "23435", "country": "United States", "geoPoint": {"lat": 36.72836, "lon": -76.58496}}, {"facility": "Local Institution", "city": "Coquitlam", "state": "British Columbia", "zip": "V3K 3V9", "country": "Canada", "geoPoint": {"lat": 49.28297, "lon": -122.75262}}, {"facility": "Local Institution", "city": "Winnipeg", "state": "Manitoba", "zip": "R3E3P4", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "Local Institution", "city": "Brampton", "state": "Ontario", "zip": "L6T 0G1", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"facility": "Local Institution", "city": "Smiths Falls", "state": "Ontario", "zip": "K7A 4W8", "country": "Canada", "geoPoint": {"lat": 44.90452, "lon": -76.02333}}, {"facility": "Local Institution", "city": "Toronto", "state": "Ontario", "zip": "M9W 4L6", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Local Institution", "city": "Granby", "state": "Quebec", "zip": "J2G 8Z9", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -72.73243}}, {"facility": "Local Institution", "city": "Saskatoon", "state": "Saskatchewan", "zip": "S7K 3H3", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "Local Institution", "city": "Quebec", "zip": "G1N 4V3", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Local Institution", "city": "Bucheon", "state": "Gyeonggi-do", "zip": "420-717", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Local Institution", "city": "Sungnam-si", "state": "Gyeonggi-do", "zip": "463-712", "country": "Korea, Republic of"}, {"facility": "Local Institution", "city": "Daegu", "zip": "700-721", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Local Institution", "city": "Incheon", "zip": "405-760", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Local Institution", "city": "Seoul", "zip": "110-774", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Seoul", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Seoul", "zip": "137-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Cuautla", "state": "Morelos", "zip": "62744", "country": "Mexico", "geoPoint": {"lat": 18.8106, "lon": -98.93525}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64710", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Merida", "state": "Yucatan", "zip": "97070", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}, {"facility": "Local Institution", "city": "Aguascalientes", "zip": "20230", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "Local Institution", "city": "Chihuahua", "zip": "31217", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "Local Institution", "city": "Durango", "zip": "34000", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Local Institution", "city": "Gdansk", "zip": "80-546", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Local Institution", "city": "Katowice", "zip": "40-057", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Local Institution", "city": "Katowice", "zip": "40954", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Local Institution", "city": "Krakow", "zip": "30-015", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Local Institution", "city": "Lodz", "zip": "90-242", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Local Institution", "city": "Opole", "zip": "45-367", "country": "Poland", "geoPoint": {"lat": 50.67211, "lon": 17.92533}}, {"facility": "Local Institution", "city": "Poznan", "zip": "61-655", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Local Institution", "city": "Pulawy", "zip": "24-100", "country": "Poland", "geoPoint": {"lat": 51.41655, "lon": 21.96939}}, {"facility": "Local Institution", "city": "Warszawa", "zip": "03-580", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Local Institution", "city": "Cidra", "zip": "00739", "country": "Puerto Rico", "geoPoint": {"lat": 18.17579, "lon": -66.16128}}, {"facility": "Local Institution", "city": "Manati", "zip": "00674", "country": "Puerto Rico", "geoPoint": {"lat": 18.42745, "lon": -66.49212}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00909", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00926", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00935", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "Villa Fontana", "zip": "00983", "country": "Puerto Rico", "geoPoint": {"lat": 18.40439, "lon": -65.9735}}, {"facility": "Local Institution", "city": "Ploiesti", "state": "Prahova", "zip": "100018", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"facility": "Local Institution", "city": "Ploiesti", "state": "Prahova", "zip": "100163", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"facility": "Local Institution", "city": "Timisoara", "state": "Timis", "zip": "300736", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Local Institution", "city": "Bucharest", "zip": "050538", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Local Institution", "city": "Bucuresti", "zip": "020359", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Local Institution", "city": "Bucuresti", "zip": "020475", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Local Institution", "city": "Bucuresti", "zip": "11794", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Local Institution", "city": "Cluj Napoca Cluj", "zip": "400006", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Local Institution", "city": "Craiova", "zip": "200349", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Local Institution", "city": "Galati", "zip": "800098", "country": "Romania", "geoPoint": {"lat": 45.45, "lon": 28.05}}, {"facility": "Local Institution", "city": "Soweto", "state": "Gauteng", "zip": "2013", "country": "South Africa", "geoPoint": {"lat": -26.26781, "lon": 27.85849}}, {"facility": "Local Institution", "city": "Gauteng", "state": "Johannesburg", "zip": "1818", "country": "South Africa"}, {"facility": "Local Institution", "city": "Durban", "state": "Kwa-Zulu Natal", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Local Institution", "city": "Cape Town", "state": "Western Cape", "zip": "7500", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Local Institution", "city": "Goodwood", "state": "Western Cape", "zip": "7460", "country": "South Africa"}, {"facility": "Local Institution", "city": "Paarl", "state": "Western Cape", "zip": "7646", "country": "South Africa", "geoPoint": {"lat": -33.73378, "lon": 18.97523}}, {"facility": "Local Institution", "city": "Rondebosch", "state": "Western Cape", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.96333, "lon": 18.47639}}, {"facility": "Local Institution", "city": "Somerset West", "state": "Western Cape", "zip": "7130", "country": "South Africa", "geoPoint": {"lat": -34.08401, "lon": 18.82113}}, {"facility": "Local Institution", "city": "Johannesburg", "zip": "1829", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Local Institution", "city": "Johannesburg", "zip": "2129", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}]}, "referencesModule": {"references": [{"pmid": "25352655", "type": "RESULT", "citation": "Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28."}, {"pmid": "31364269", "type": "DERIVED", "citation": "Bailey CJ, Del Prato S, Wei C, Reyner D, Saraiva G. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes Obes Metab. 2019 Nov;21(11):2564-2569. doi: 10.1111/dom.13841. Epub 2019 Aug 26."}, {"pmid": "30304106", "type": "DERIVED", "citation": "Rosenstock J, Mathieu C, Chen H, Garcia-Sanchez R, Saraiva GL. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018 Aug;62(4):424-430. doi: 10.20945/2359-3997000000056."}], "seeAlsoLinks": [{"label": "BMS clinical trial educational resource", "url": "http://www.bms.com/studyconnect/Pages/home.aspx"}, {"label": "CV_181169_Protocol_Redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3665&filename=CV_181169_Protocol_Redacted.pdf"}, {"label": "CV181169_Synopsis", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3665&filename=CV181169_Synopsis.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of 1282 participants enrolled subjects, 534 eligible subjects entered the randomized, double-blind treatment period.\n\nOf 534 randomized and treated subjects, 490 subjects completed the study.", "groups": [{"id": "FG000", "title": "Arm 1: Saxagliptin+Metformin XR+Placebo", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "FG001", "title": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "FG002", "title": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "176"}, {"groupId": "FG001", "numSubjects": "179"}, {"groupId": "FG002", "numSubjects": "179"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "161"}, {"groupId": "FG001", "numSubjects": "160"}, {"groupId": "FG002", "numSubjects": "169"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Reason 'Other' in the protocol", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "discontinue study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Poor/Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Arm 1: Saxagliptin+Metformin XR+Placebo", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "BG001", "title": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "BG002", "title": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "176"}, {"groupId": "BG001", "value": "179"}, {"groupId": "BG002", "value": "179"}, {"groupId": "BG003", "value": "534"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.6", "spread": "9.6"}, {"groupId": "BG001", "value": "53.5", "spread": "9.7"}, {"groupId": "BG002", "value": "53.4", "spread": "9.8"}, {"groupId": "BG003", "value": "53.8", "spread": "9.7"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "148"}, {"groupId": "BG001", "value": "158"}, {"groupId": "BG002", "value": "160"}, {"groupId": "BG003", "value": "466"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "68"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "94"}, {"groupId": "BG003", "value": "266"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "94"}, {"groupId": "BG001", "value": "89"}, {"groupId": "BG002", "value": "85"}, {"groupId": "BG003", "value": "268"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "121"}, {"groupId": "BG001", "value": "131"}, {"groupId": "BG002", "value": "120"}, {"groupId": "BG003", "value": "372"}]}]}, {"title": "Black african/american", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "22"}, {"groupId": "BG003", "value": "60"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "33"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "25"}, {"groupId": "BG003", "value": "69"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.8", "spread": "5.142"}, {"groupId": "BG001", "value": "31.46", "spread": "5.321"}, {"groupId": "BG002", "value": "31.76", "spread": "4.787"}, {"groupId": "BG003", "value": "31.67", "spread": "5.080"}]}]}]}, {"title": "T2DM duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.2", "spread": "5.52"}, {"groupId": "BG001", "value": "7.4", "spread": "5.40"}, {"groupId": "BG002", "value": "7.1", "spread": "5.04"}, {"groupId": "BG003", "value": "7.6", "spread": "5.33"}]}]}]}, {"title": "HbA1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.03", "spread": "1.05"}, {"groupId": "BG001", "value": "8.87", "spread": "1.16"}, {"groupId": "BG002", "value": "8.92", "spread": "1.18"}, {"groupId": "BG003", "value": "8.94", "spread": "1.13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.", "populationDescription": "All randomized participants who received study medication and had nonmissing HbA1c values at baseline and Week 24", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "% HbA1c", "timeFrame": "Baseline (Week 0) and at Week 24", "groups": [{"id": "OG000", "title": "Arm 1: Saxagliptin+Metformin XR+Placebo", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG001", "title": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG002", "title": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.88", "lowerLimit": "-1.03", "upperLimit": "-0.72"}, {"groupId": "OG001", "value": "-1.20", "lowerLimit": "-1.35", "upperLimit": "-1.04"}, {"groupId": "OG002", "value": "-1.47", "lowerLimit": "-1.62", "upperLimit": "-1.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Primary endpoint was tested at alpha=0.05; significance was claimed only if Saxagliptin+Dapagliflozin+Metformin was superior to both Saxagliptin+Metformin and Dapagliflozin+Metformin.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.81", "ciUpperLimit": "-0.37", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1112"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0166", "pValueComment": "Primary endpoint was tested at alpha=0.05; significance was claimed only if Saxagliptin+Dapagliflozin+Metformin was superior to both Saxagliptin+Metformin and Dapagliflozin+Metformin.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.48", "ciUpperLimit": "-0.05", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1108"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at week 24 in the doubleblind period, including observations prior to rescue.", "populationDescription": "All randomized participants who received study medication and had nonmissing PPG values at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "MG/DL PPG", "timeFrame": "Baseline (Week 0) and at Week 24", "groups": [{"id": "OG000", "title": "Arm 1: Saxagliptin+Metformin XR+Placebo", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG001", "title": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG002", "title": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "144"}, {"groupId": "OG002", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-35.6", "spread": "3.510", "lowerLimit": "-42.5", "upperLimit": "-28.7"}, {"groupId": "OG001", "value": "-70.4", "spread": "3.538", "lowerLimit": "-77.4", "upperLimit": "-63.5"}, {"groupId": "OG002", "value": "-79.6", "spread": "3.426", "lowerLimit": "-86.3", "upperLimit": "-72.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "LOCF", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Each secondary endpoint was tested at alpha=0.05; significance was claimed only if Saxagliptin+Dapagliflozin+Metformin was superior to both Saxagliptin+Metformin and Dapagliflozin+Metformin.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-44.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-53.7", "ciUpperLimit": "-34.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.914"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "LOCF", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0639", "pValueComment": "Each secondary endpoint was tested at alpha=0.05; significance testing stops at the endpoint where p-value\\>0.05.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.8", "ciUpperLimit": "0.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.923"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.", "populationDescription": "All randomized participants who received study medication and had nonmissing PPG values at baseline and Week 24", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline (Week 0) and at Week 24", "groups": [{"id": "OG000", "title": "Arm 1: Saxagliptin+Metformin XR+Placebo", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG001", "title": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG002", "title": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "155"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.0", "lowerLimit": "-19.6", "upperLimit": "-8.4"}, {"groupId": "OG001", "value": "-31.7", "lowerLimit": "-37.3", "upperLimit": "-26.2"}, {"groupId": "OG002", "value": "-37.8", "lowerLimit": "-43.2", "upperLimit": "-32.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-23.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-31.6", "ciUpperLimit": "-15.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.988", "estimateComment": "ANCOVA was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\\>0.05."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.8", "ciUpperLimit": "1.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.957", "estimateComment": "ANCOVA was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\\>0.05."}]}, {"type": "SECONDARY", "title": "Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Therapeutic glycemic response is defined as HbA1c \\<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "populationDescription": "All randomized participants who received study medication and were not missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "% of Participants", "timeFrame": "At Week 24", "groups": [{"id": "OG000", "title": "Arm 1: Saxagliptin+Metformin XR+Placebo", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG001", "title": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG002", "title": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "175"}, {"groupId": "OG001", "value": "173"}, {"groupId": "OG002", "value": "177"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.3", "lowerLimit": "13.0", "upperLimit": "23.5"}, {"groupId": "OG001", "value": "22.2", "lowerLimit": "16.1", "upperLimit": "28.3"}, {"groupId": "OG002", "value": "41.4", "lowerLimit": "34.5", "upperLimit": "48.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean difference in percentages", "paramValue": "23.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "14.7", "ciUpperLimit": "31.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.282", "estimateComment": "Modified Logistic Regression was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\\>0.05."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean difference in percentages", "paramValue": "19.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10.1", "ciUpperLimit": "28.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.587", "estimateComment": "Modified Logistic Regression was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\\>0.05."}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Body Weight at Week 24", "description": "Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.", "populationDescription": "All randomized participants who received study medication and had nonmissing body weight values at baseline and Week 24", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Body weight Kg", "timeFrame": "Baseline (Week 0) and at Week 24", "groups": [{"id": "OG000", "title": "Arm 1: Saxagliptin+Metformin XR+Placebo", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG001", "title": "Arm 2: Dapagliflozin+Metformin XR+Placebo", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks"}, {"id": "OG002", "title": "Arm 3: Saxagliptin+Dapagliflozin+Metformin XR", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.48", "upperLimit": "0.49"}, {"groupId": "OG001", "value": "-2.39", "lowerLimit": "-2.87", "upperLimit": "-1.91"}, {"groupId": "OG002", "value": "-2.05", "lowerLimit": "-2.52", "upperLimit": "-1.58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.73", "ciUpperLimit": "-1.37", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3451", "estimateComment": "ANCOVA was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\\>0.05."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "24 weeks", "eventGroups": [{"id": "EG000", "title": "SAXA + MET", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matching with Dapagliflozin Tablets, Oral, 0mg, Once daily, 24 weeks", "seriousNumAffected": 6, "seriousNumAtRisk": 176, "otherNumAffected": 0, "otherNumAtRisk": 176}, {"id": "EG001", "title": "DAPA + MET", "description": "Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo matching with Saxagliptin Tablets, Oral, 0mg, Once daily, 24 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 179, "otherNumAffected": 0, "otherNumAtRisk": 179}, {"id": "EG002", "title": "SAXA + DAPA + MET", "description": "Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, \u2265 1500mg/\u2264 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148", "seriousNumAffected": 2, "seriousNumAtRisk": 179, "otherNumAffected": 0, "otherNumAtRisk": 179}], "seriousEvents": [{"term": "ACUTE MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 179}]}, {"term": "PANCREATITIS CHRONIC", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 179}]}, {"term": "UMBILICAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "CHEST PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "TOOTH INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "PATELLA FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "HYPERKALAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "ARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "GASTRIC NEOPLASM", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 179}]}, {"term": "TRANSIENT ISCHAEMIC ATTACK", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "BENIGN PROSTATIC HYPERPLASIA", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "PULMONARY EMBOLISM", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}, {"term": "DEEP VEIN THROMBOSIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 179}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Boaz Hirshberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}